Trial Profile
A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Quizartinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 07 Feb 2024 Planned number of patients changed from 52 to 72.
- 07 Feb 2024 Status changed from active, no longer recruiting to recruiting.
- 12 Dec 2023 Results reporting safety and efficacy data with a median follow-up of 15 months presented at the 65th American Society of Hematology Annual Meeting and Exposition